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BACKGROUND: Antimicrobial stewardship (AMS) programs have shown to reduce the emergence of 
antimicrobial resistance (AMR) and health-care-associated infections (HAIs), and save health-care costs 
associated with an inappropriate antimicrobial use. The primary objective of this study was to compare 
the consumption and cost of antimicrobial agents using defined daily dose (DDD) and direct cost of 
antibiotics before and after the AMS program implementation. Secondary objective was to determine the 
rate of HAIs [Clostridium difficile (C. difficile), ventilator-associated pneumonia (VAP), and central line-
associated bloodstream infection (CLABSI) before and after the AMS program implementation. 
METHODS: This is a pre-post quasi-experimental study. Adult inpatients were enrolled in a prospective 
fashion under the active AMS arm and compared with historical inpatients who were admitted to the 
same units before the AMS implementation. Study was conducted at four tertiary private hospitals 
located in two cities in Saudi Arabia. Adult inpatients were enrolled under the pre- AMS arm and post- 
AMS arm if they were on any of the ten selected restricted broad-spectrum antibiotics (imipenem/
cilastatin, piperacillin/tazobactam, colistin, tigecycline, cefepime, meropenem, ciprofloxacin, moxifloxacin, 
teicoplanin and linezolid). RESULTS: A total of 409,403 subjects were recruited, 79,369 in the pre- AMS 
control and 330,034 in the post- AMS arm. Average DDDs consumption of all targeted broad-spectrum 
antimicrobials from January 2016 to June 2019 post- AMS launch was lower than the DDDs use of these 
agents pre- AMS (233 vs 320 DDDs per 1000 patient-days, p = 0.689). Antimicrobial expenditures 
decreased by 28.45% in the first year of the program and remained relatively stable in subsequent years, 
with overall cumulative cost savings estimated at S.R. 6,286,929 and negligible expenses of S.R. 505,115 
(p = 0.648). Rates of healthcare associated infections involving C. difficile, VAP, and CLABSI all decreased 
significantly after AMS implementation (incidence of HAIs in 2015 compared to 2019: for C. difficile, 94 vs 
13, p = 0.024; for VAP, 24 vs 6, p = 0.001; for CLABSI, 17 vs 1, p = 0.000; respectively). CONCLUSION: 
Implementation of AMS program at HMG healthcare facilities resulted in reduced antimicrobials use and 
cost, and lowered incidence of healthcare associated infections. 
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Abstract
Background: Antimicrobial stewardship (AMS) programs have shown to reduce the emergence of antimicrobial
resistance (AMR) and health-care-associated infections (HAIs), and save health-care costs associated with an
inappropriate antimicrobial use. The primary objective of this study was to compare the consumption and cost of
antimicrobial agents using defined daily dose (DDD) and direct cost of antibiotics before and after the AMS
program implementation. Secondary objective was to determine the rate of HAIs [Clostridium difficile (C. difficile),
ventilator-associated pneumonia (VAP), and central line-associated bloodstream infection (CLABSI) before and after
the AMS program implementation.
Methods: This is a pre-post quasi-experimental study. Adult inpatients were enrolled in a prospective fashion under
the active AMS arm and compared with historical inpatients who were admitted to the same units before the AMS
implementation. Study was conducted at four tertiary private hospitals located in two cities in Saudi Arabia. Adult
inpatients were enrolled under the pre- AMS arm and post- AMS arm if they were on any of the ten selected
restricted broad-spectrum antibiotics (imipenem/cilastatin, piperacillin/tazobactam, colistin, tigecycline, cefepime,
meropenem, ciprofloxacin, moxifloxacin, teicoplanin and linezolid).
Results: A total of 409,403 subjects were recruited, 79,369 in the pre- AMS control and 330,034 in the post- AMS
arm. Average DDDs consumption of all targeted broad-spectrum antimicrobials from January 2016 to June 2019
post- AMS launch was lower than the DDDs use of these agents pre- AMS (233 vs 320 DDDs per 1000 patient-days,
p = 0.689). Antimicrobial expenditures decreased by 28.45% in the first year of the program and remained relatively
stable in subsequent years, with overall cumulative cost savings estimated at S.R. 6,286,929 and negligible expenses of
S.R. 505,115 (p = 0.648). Rates of healthcare associated infections involving C. difficile, VAP, and CLABSI all decreased
significantly after AMS implementation (incidence of HAIs in 2015 compared to 2019: for C. difficile, 94 vs 13, p = 0.024;
for VAP, 24 vs 6, p = 0.001; for CLABSI, 17 vs 1, p = 0.000; respectively).
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Conclusion: Implementation of AMS program at HMG healthcare facilities resulted in reduced antimicrobials use and
cost, and lowered incidence of healthcare associated infections.
Keywords: Antimicrobial agents, Broad-spectrum antibiotics, Consumption, Cost, Defined daily dose, Healthcare
associated infections, Saudi Arabia
Introduction
For decades microbes, in particular bacteria, have be-
come increasingly resistant to various antimicrobials.
The World Health Assembly’s endorsement of the Glo-
bal Action Plan on Antimicrobial Resistance (AMR) [1]
in May 2015, and the Political Declaration of the High-
Level Meeting of the General Assembly on AMR [2] in
September 2017, both recognize AMR as a global threat
to public health. These policy initiatives acknowledge
overuse and misuse of antimicrobials as a main driver
for development of resistance, as well as a need to
optimize the use of antimicrobials.
Antimicrobial stewardship (AMS) is a coherent set of
actions which promote the responsible use of antimicro-
bials. This definition can be applied to actions at the in-
dividual level as well as the national and global level, and
across human health, animal health and the environment
[3, 4]. Antimicrobial stewardship programs optimize the
use of antimicrobials, improve patient outcomes, reduce
AMR and health-care-associated infections (HAIs), and
save health-care costs amongst others [5, 6].
Many countries around the world have developed and
are implementing their national action plans (NAPs) on
AMR, [7] in which AMS is a key priority. Although there
is a scientific evidence base for AMS, [8] and national,
regional and global guidance documents exist, [9–13]
there is a growing need for more specific guidance on
how to establish, implement and evaluate effective AMS
programs at the national and health-care-facility level
[11, 14].
AMS programs result in significant decreases in anti-
microbial consumption and cost and improve infections
due to specific antimicrobial-resistant pathogens and the
overall hospital length of stay as well [5, 6]. Future stud-
ies should focus on the sustainability of these outcomes
and evaluate potential beneficial long-term effects of
AMS programs in mortality and infection rates [15].
As stewardship programs can lower unnecessary con-
sumption and cost of antimicrobials [5, 6], Al Habib
Medical Group (HMG) established, created and imple-
mented a stepwise AMS program and guidelines for
antimicrobial use within its healthcare facilities.
Study purpose
This study aimed to measure AMS program impact by
comparing a One-year baseline period prior to the
implementation of the AMS to Four years of follow-up
data after the program was initiated in terms of re-
stricted antimicrobials use and cost, and rate of health-
care associated infections (HAIs) occurrence in adult
inpatients hospitalized at four HMG healthcare facilities
(Olaya, Altakhassusi, Arryan and Qassim) in Saudi
Arabia.
Settings
Habib Medical Group (HMG) is globally distinguished
as one of the largest healthcare providers of comprehen-
sive healthcare services in the Middle Eastern region and
aims towards providing excellence in various specialized
healthcare services to fulfill all patients’ needs. There-
fore, the medical group is currently operating 22 medical
facilities across Saudi Arabia, United Arab Emirates
UAE and Bahrain, including 7 hospitals and 6 medical
centers. All HMG medical facilities are working accord-
ing to the highest international standards.
Study was conducted at four HMG tertiary and spe-
cialized health facilities with adequate medical profes-
sional resources including: Dr. Sulaiman Al Habib Olaya
Medical Complex: a 195-bed capacity, Dr. Sulaiman Al
Habib Hospital in Altakhassusi: a 237-bed capacity, and
Dr. Sulaiman Al Habib Arryan Hospital: a 365-bed cap-
acity, in Riyadh; and Dr. Sulaiman Al Habib Qassim
Hospital: a 150-bed capacity, in Qassim, Saudi Arabia.
These facilities provide healthcare to a wide range of
patients in various specialties and subspecialties, includ-
ing maternity and children, general medicine and sur-
gery, cardiac surgeries, bone, joint and spine surgery,
dermatology and plastic surgery, ophthalmology and
laser or vision correction surgery, neurosurgery, obesity
surgery, intensive care unit, dialysis, hematological and
solid organ malignancies, and sports injuries. Yearly,
these four healthcare facilities encounter over 152,995
surgical cases, nearly 2,152,441 emergency department
visits, and over 409,403 admissions.
AMS program
AMS program has been implemented at HMG medical
settings since January 2016 to optimize the use of antibi-
otics; reduce further emergence, selection and spread of
AMR; decrease the consumption of broad-spectrum an-
timicrobials; reduce the rate of HAIs and other
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multidrug resistant organisms; and save on unnecessary
health-care costs.
HMG medical facilities adapt different types of AMS
interventions to improve antibiotic prescribing have
proven successful [5]. These AMS interventions include
education (prescribers and other healthcare workers)
[16], and/or audit and feedback activities (real-time, ei-
ther written or oral, or retrospective), [17] and/or re-
strictive interventions, such as pre-authorization of
targeted antibiotics [18]. Restrictive interventions, a core
strategy that provide the foundation for an AMS pro-
gram, have been shown to provide immediate and sig-
nificant reduction in antibiotic use and cost [17, 18]. All
four HMG facilities restrict a group of antibiotics that
should be reserved for treatment of confirmed or sus-
pected infections due to multi drug-resistant organisms,
and treated as “last-resort” options. Use of restricted an-
tibiotics may be limited to certain indications, pre-
scribers, services, patient populations or a combination
of these. A practical approach that allows attending
physician to use the drug pending approval by physician
and/or pharmacist or AMS team after +/− 48 h.
Methods
Study design
A pre-post quasi-experimental study design was used to
analyze the clinical outcomes of the AMS by comparing
antimicrobial utilization and cost, and rate of HAIs oc-
currence data for designated periods before (January
2015– December 2015) and after (January 2016–June
2019) AMS program initiation in adult inpatients hospi-
talized at four HMG medical facilities in Saudi Arabia:
Olaya, Altakhassusi, Arryan and Qassim.
Data collection
In January 2015, we began using data-mining software to
develop automated reports to capture key pharmacy, cost
and microbiological data on all adult hospital inpatients
receiving those the following 10 restricted antimicrobials:
imipenem/cilastatin, piperacillin/tazobactam, colistin, tige-
cycline, cefepime, meropenem, ciprofloxacin, moxifloxa-
cin, teicoplanin and linezolid. Data were collected to
evaluate the impact of AMS interventions (baseline and
follow-up data) on use of those 10 restricted antibiotics to
identify areas for improvement of antibiotic prescribing
for the whole HMG organization, a department or ward;
and to provide regular and structured feedback both on
the quality and quantity of antibiotic prescribing and use
to prescribers. Data of a five-year analysis were compared
for time-related changes in antimicrobials consumption
and cost, and HAIs incidence rate pre- and post- AMS
program implementation.
Data were collected in separate customized Excel
spreadsheets (version 2019; Microsoft Corp, Redmond,
WA). Antibacterials that were high cost, high use, or re-
quired preservation due to the potential for resistance is-
sues to develop were included. No data for restricted
antimicrobials use in adult inpatients in all departments
and units at the targeted four HMG health facilities were
excluded. All adult patients admitted during the study
period and received at least one dose of one of the re-
stricted antimicrobials were included. Exclusion criteria
included age less than 18 years, consumption of antimi-
crobials not included in the study, and consumption of
antimicrobial by a route other than parenteral or oral
routes.
Data regarding drug consumption were gathered from
our electronic prescribing records, pharmacy dispensing
data and electronic medication administration records
and reported in terms of defined daily doses (DDDs), as
recommended by the WHO Collaborating Centre for
Drug Statistics Methodology [19]. Antimicrobial
utilization was calculated based on the defined daily dose
per 1000 acute patient days (DDD/1000 patient days).
The DDD per 1000 patient days was calculated by divid-
ing the cumulative use of a specific antimicrobial (in
grams) by a defined daily standard dose for that drug
and then expressing it per every 1000 acute patient days.
The acquisition costs of all parenteral and oral anti-
microbial agents given to adult inpatients were collected
and compared over a five-year time frame. Current ac-
quisition prices were used for all cost comparisons to ac-
count for any changes in those costs over the studied
period. Antimicrobial cost data included purchases made
through the hospital’s pharmaceutical wholesaler and
direct purchases from the manufacturer. Total expendi-
tures for all antimicrobials were calculated and divided
by the applicable total number of patient-days to derive
a figure for “Antimicrobial Riyals Per Patient Day”
(ARPD). Actual cost savings related to the AMS were
calculated by subtracting the ARPD for each of the four
study years (2016–2019) from the ARPD for 2015, the
baseline year (i.e., the year before the start of the AMS);
each difference was then multiplied by the number of
patient-days for the specific year.
The impact of the AMS program on HAIs involving
Clostridium difficile (C. difficile), ventilator-associated
pneumonia (VAP), and central line-associated blood-
stream infection (CLABSI) was determined by following
the occurrence rates before and after AMS program
launch. Sources of gathered data on HAIs incidence
were retrieved from the microbiology, epidemiology, and
infection control surveillance databases.
The institutional review board at HMG approved this
study as exempt from the full board review and waived
the need for informed consent because of the use of
existing data and the information being recorded in a
way that subjects cannot be individually identified.
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Statistical analysis
Continuous variables were presented as sums and
means. Categorical variables were presented as frequen-
cies and percentages. Descriptive statistics, testing for
changes in antibiotic use and cost and rate of HAIs inci-
dence data was made by simple calculations, estimating
frequency and percentage differences between two or
more values, and creating combo charts were made by
Excel (version 2019; Microsoft Corp, Redmond, WA).
The pre- and post-AMS periods were compared for
time-related changes in HAIs, antimicrobial use, and
ARPD by analyzing analysis of variance (ANOVA). The
overall levels of infection were compared between the
pre- and post-AMS periods through analysis of variance.
The a priori level of significance was 0.05.
Results
There was little variation during the study period with
respect to the total number of hospital admissions in all
HMG four facilities (79,369 in 2015, 80,586 in 2016, 78,
257 in 2017, 82,049 in 2018, and 89,142 in 2019), and
emergency room visits (364,167, 456,224, 399,139, 433,
616 and 499,295), reflecting a relatively stable inpatient
hospital population during the time period evaluated.
A total of 409,403 patients were involved in our study,
among whom 79,369 patients were involved before the
AMS program implementation corresponding to 163,
024 patient days and an average of 330,034 patients were
involved after the AMS interventions making up an
average of 7,788,385 patient days between 2016 to 2019.
Antimicrobial consumption, expressed as DDDs per
1000 patient-days, had risen in the years before the AMS
program launch. Individual restricted antimicrobial con-
sumption before and after AMS program beginning and
rate of HAIs incidence is shown in Fig. 1. The most con-
sumed antimicrobial agents (as total of DDDs in all facil-
ities over 5 years) included ciprofloxacin (365 DDDs),
teicoplanin (217 DDDs), linezolid (175 DDDs), and mer-
openem (173 DDDs). The least frequently consumed
antimicrobial agents (as total of DDDs in all facilities
over 5 years) included moxifloxacin (17 DDDs), cefepime
(27 DDDs), colistin (46 DDDs), and imipenem/cilastatin
(50 DDDs). Almost all (100%) antimicrobial consump-
tion was administered parenterally.
As shown in Fig. 1, the use of almost all antibiotic
classes trended downward in the year after AMS pro-
gram commencement; the year to year change in DDD
values did not differed significantly between the pre- and
post- AMS periods (p = 0.689).
Notably, average total linezolid use in the one pre-
AMS year was 66 DDDs per 1000 patient-days; overall
linezolid use fell by to an average of 70% to an average
of 20 DDDs per 1000 patient-days. Similarly, teicoplanin
use reduced from 68 to 30 DDDs per 1000 patient-days
Fig. 1 Restricted antimicrobials use and rate of HAIs occurrence before and after implementation of AMS program in all four HMG medical
facilities, 2015–2019. Abbreviations: c. diff, Clostridium difficile; CLABSI, central line-associated bloodstream infection; DDD, defined daily dose; HAIs,
healthcare associated infections; VAP, ventilator-associated pneumonia
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(a 56% decrease of drug’s average total consumption).
Ciprofloxacin was the most used antibiotic of all selected
agents and its use steadily rose to a peak of 85 DDDs
per 1000 patient-days in 2019. Imipenem/cilastatin, tige-
cycline and cefepime were almost consumed at equal
DDDs throughout the study period. Moxifloxacin con-
sumption declined from 17 DDDs per 1000 patient-days
to zero post AMS implementation and remained at this
nil level on the following years.
Before the AMS intervention, we observed a high inci-
dence of C. difficile, VAP, and CLABSI, which were the
most common of HAIs in the targeted HMG medical fa-
cilities. HAIs rates for C. difficile, VAP, and CLABSI re-
duced significantly in 2019 after AMS program was
implemented for almost 4 yrs in comparison to pre-
AMS program (for C. difficile, reduced by 86.17%, p =
0.024; for VAP, reduced by 75%, p = 0.001, for CLABSI,
reduced by 94.12%, p = 0.000; respectively, Fig. 1).
As the antibiotic consumption decreased after AMS
implementation, the proportion of HAIs at the HMG fa-
cilities correspondingly decreased. The total consump-
tion of antibacterial agents each year during the study
period had a significant positive relationship with HAIs
in hospitalized ill patients at the time of admission each
year. The between-period difference in rates of health
associated CLABSI infections was fluctuating possibly
because of the non-adherence of prescribers to AMS
guidelines, overuse, or improper use of antibiotics.
After the initiation of the AMS program in 2016, total
DDDs use of all restricted antimicrobials values gener-
ally declined. Average total DDDs of all antimicrobials
use for the period from 2016 to 2019 was lower than the
total DDDs of all antimicrobials consumption in 2015
(72,690 vs 99,420 DDDs). Total DDDs consumption of
the all antimicrobials in 2015 fell remarkably by 44.8% in
2019. Total antimicrobial consumption and antimicro-
bial riyals per patient-day before and after AMS initi-
ation is shown in Fig. 2.
ARPD, which had risen steadily before AMS start, de-
creased by 33.32% in the first year after AMS implemen-
tation (2016), but increased by 4.48% in 2017; this trend
was due almost exclusively to the continuous increased
use of ciprofloxacin experienced over a period of several
years. ARPD fell by 22.23% in 2018; and rose by 2.14%
in 2019, a similar ARPD pre- AMS implementation, at-
tributed to the biggest DDDs consumption for ciproflox-
acin of all restricted antimicrobials throughout the
whole 5 yrs (p = 0.648) (Table 1). Use of ciprofloxacin
was high due to many advantageous pharmacokinetic
properties including high oral bioavailability, large vol-
ume of distribution, and broad-spectrum antimicrobial
activity against aerobic, enteric gram-negative bacilli (eg,
Fig. 2 Total restricted antimicrobials consumption in all four HMG medical facilities before and after implementation of AMS Program, expressed
as defined daily doses (DDDs) per 1000 patient-days (bars) and antimicrobial riyals per patient day (ARPD, indicated by solid line)
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Enterobacteriaceae, including Escherichia coli, Klebsiella
spp., Proteus spp) [20]. Another reason for intravenous
ciprofloxacin high usage was related to the practice of
using the drug as a combination therapy with other anti-
infectives in hospitalized patients (eg, diabetic foot,
intra-abdominal, and pneumonia infections) [21].
For 2016–2019, the actual cost savings and expenses
attributable to AMS activities ranged from S.R. 2,173,
668 to S.R. 4,113,261 considered as high savings, and
S.R. 392,342 to S.R. 112,774 supposedly regarded as low
expenses.
Discussion
Metrics for assessing the impact of AMS program on
antibiotic use within a healthcare facility are essential
part of any AMS strategy to identify problems or evalu-
ate the benefits of AMS interventions [5, 6, 9–13]. Be-
cause assessing all indicators is unrealistic, we were
encouraged to select the most relevant and feasible met-
rics for our particular settings. We utilized the DDDs,
the most common and sustainable measure and least la-
borious way [22], which is suitable for the age category
of our study participants [23].
A main finding in this study is the high consumption
of ciprofloxacin that confirms the results of previous
studies on using this restricted broad-spectrum anti-
biotic within Saudi Arabia [24–26]. Resistance to cipro-
floxacin is growing locally [25, 27, 28] and worldwide
[29, 30]and is commonly reported in most target bac-
teria [25, 27–30], use of ciprofloxacin should be gener-
ally reserved for complicated infections in which the
benefits of use clearly outweigh the risks. The best ap-
proach to control the growing resistance is to control
the use of ciprofloxacin and other fluoroquinolones use
coupled with adherence to infection control measures to
prevent spread of resistant strains among patients [5].
Surveillance of resistance pattern of prevalent strains
and reduction of antibiotic consumption are essential for
hospital prescribing policy and use of antibiotics [6].
Comparison of the antimicrobials consumption at the
HMG health settings expressed as the DDDs per 1000
patient-days in this study with local data is not possible
or very hard. Differences are not only limited to the total
amount consumed but also related to the various anti-
microbial classes used [9, 10, 24, 26, 31]. Comparing
HMG findings on antimicrobials DDDs consumption to
local data may help to identify hospital units or wards of
highest use, to monitor the impact for future interven-
tions, and to feedback prescribing physicians with the
prescription patterns [26].
Currently, only one local study reported on the com-
parable efficacy of an AMS program on antimicrobial
DDDs consumption per 1000 patient days before and
after the intervention among hospitalized patients [9]. In
general, findings of local studies on antimicrobial con-
sumption are incomparable to our data because they dif-
fer in study design (retrospective [9, 24, 31] or
prospective [10, 26]), type of AMS interventions (formu-
lary restriction; preapproval strategies; and prospective
audit and feedback [9], cascade reporting of antimicro-
bial susceptibilities (antibiogram); education; automatic
stop orders; and formulary restriction [10], no specific
AMS interventions were made [24], education; antibio-
gram; iv-to-oral switch; de-escalation; dose adjustment;
and therapeutic drug monitoring of vancomycin [31],
guidelines; formulary restriction; and activated AMS
team [26]), age group (adults only [9, 26, 31], or children
and adults [10, 24]), type of setting (medical 20-bed ICU
(of 894-bed tertiary hospital) [9], general 5-bed ICU (of
380-bed general hospital) [10, 24, 31], tertiary 11-bed
ICU (of 1000-bed hospital) [26]), antimicrobial con-
sumption metric type (DDDs / 1000 patient-days [9, 10],
DDDs / 100 patient-days [24, 31], DDDs and DOTs /
1000 patient-days [26]), and antimicrobial selection (≤ 5
restricted broad-spectrum agents [9], or > 5 restricted
broad-spectrum agents [10, 24, 26, 31]). However, the
average consumption of piperacillin/tazobactam, colistin,
and tigecycline expressed in DDDs per 1000 patient-
days post- AMS program in this study was a lot lower
than the rates reported in a local report (21 vs 145, 10 vs
117, and 17 vs 21, respectively) [26].
In addition, we report much lower average consump-
tion of ciprofloxacin and imipenem/cilastatin than rates
reported in another local study when we convert their
Table 1 Estimated cost savings and expenses associated with the AMS program implemented at the four HMG medical facilities
between 2016 and 2019
year Total antimicrobial expenditures (S.R.) Patient-Days ARPD (S.R.)a Actual savings and expenses compared with 2015 (S.R.)b
2015 11,502,287 173,297 66.37
2016 8,229,378 185,958 44.25 4,113,261
2017 9,163,568 132,150 69.34 - 392,342
2018 7,601,056 147,269 51.61 2,173,668
2019 5,361,239 79,075 67.79 - 112,774
aARPD = antimicrobial riyals per patient-day
bCalculated by subtracting the year’s ARPD from 2015’s ARPD and multiplying the result by the number of patient-days for the year. Total actual savings and
expenses for 2016–2019, S.R. 6,286,929 (high savings) and S.R. 505,115 (low expenses)
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findings for the use of those two agents to be in DDDs
per 1000 patient-days (72 vs 820, and 10 vs 52, respect-
ively) [24]. Benchmarking antimicrobial consumption
can improve the value of these data sources and can lead
to more tailored and effective reduction measures.
Variations of antimicrobials consumption can be due
to multiple factors, such as demographic characteristics,
patient mix and severity of illness, awareness and educa-
tion of healthcare providers and/or if they adhere to
AMS guidelines. These differences should be taken into
account when aiming to implement targeted interven-
tions to reduce antimicrobial consumption.
The results of our study are in line with many studies
that reported a statistically significant reduction in the
rate of C. difficile [32–35], VAP [36–38], and CLABSI
[39–41] following AMS implementation and showed
that AMS interventions were associated with shorter
duration of antibiotic therapy, less inappropriate anti-
microbial use, and neutral effect in healthcare associated
infections rates.
The implementation of the AMS program was associ-
ated with a decrease in the overall use of antimicrobials
and a decrease in antimicrobial expenditures as reported
in similar studies [42–44]. However, there are many in-
direct expenses which are expected to decrease propor-
tionally, such as from antibiotic side effects and
resistance, earlier transition to oral therapy, the discon-
tinuation of unnecessary antimicrobial agents, increased
length of hospital stay and readmission, and hospital-
acquired infections which should be taken into consider-
ation to support the implementation of AMS program.
Limitations
The success of AMS program at HMG facilities must be
considered in the context of several limitations. First,
our study was limited by its pre-post quasi-experimental
design, an empirical study used to estimate the causal
impact of AMS program intervention on target popula-
tion without random assignment. The findings could
therefore suggest an association between AMS activities
and reduced HAIs infection rates but could not establish
definite causality. However, we believe the use of that
design methodology was appropriate, as the random as-
signment of patients to an experimental group is gener-
ally not feasible.
Second, lack of demographic data of participants that
would enhance applicability of study findings and attain
a higher level for reporting key variables needed for con-
clusions and interpretation. Third, our study was not a
true cost–benefit analysis but instead only provided an
overview of the program’s implementation, resource
utilization, and observed benefits.
Fourth, the AMS program was implemented without
waiting to capture baseline quality data for longer than a
year. Finally, secondary outcomes such as changes in
length of stay of patients or readmission within 30 days
after discharge were not calculated due to the difficulty
in capturing the data for this subpopulation via elec-
tronic record query. Although antimicrobial resistance
patterns were collected, evaluation of the AMS impact
on resistance patterns was not included because that is
beyond the scope of this paper. However, in almost all
cases, trends were detected that suggested that the AMS
program had a remarkable impact on decreasing anti-
microbial utilization and cost while increasing quality of
care.
Conclusion
Antimicrobial stewardship program implementation at
four Habib Medical Group (HMG) medical facilities was
associated with a reduction in the consumption and cost
of several broad-spectrum antimicrobial agents. It was
also associated with lower incidence of healthcare associ-
ated infections within these hospitals, namely Clostrid-
ium difficile (C. difficile), ventilator-associated
pneumonia (VAP), and central line-associated blood-
stream infection (CLABSI). It might be the time to adopt
such a program at a national level in all Saudi healthcare
institutes to improve the quality of care provided and
enhance patient safety measures. Future studies should
analyze each component of AMS programs separately,
while long-term evaluation of the effect of AMS pro-
grams is also warranted to determine their lasting influ-
ence on mortality and infection rates.
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